Vertex Pharmaceuticals Incorporated (VRTX) Dividend History
Income profile from 1991 to 2025 with payout safety and yield-on-cost trend
VRTX Dividend Income Check
Safety
Payout ratio data not available yet.
Consistency
0 straight years of dividend increases.
Income Trend
Yield on cost trend needs more history.
VRTX Dividend Scorecard
Yield & Income
Payout Safety
Growth
Total Returns
Uses precomputed total return metrics from screening data (not lot-by-lot dividend reinvestment transactions). Different time windows can produce different outcomes depending on market regime and entry point.
VRTX Dividend History
No dividend payment history available
Dividend Analysis
Payout Safety
Vertex Pharmaceuticals Incorporated has limited earnings payout data (Unknown).
Piotroski F-Score: 4/9 — moderate financial health.
Growth Track Record
VRTX does not have a current streak of consecutive dividend increases.
Total Shareholder Returns
Beyond cash dividends, VRTX returns capital through share repurchases. The combined picture: 1.9% buyback yield, 1.9% total shareholder yield.
Income Trend & Total Return
The 5-year total return is 98.4%.
DRIP Growth
A $10,000 investment made 10 years ago with dividends reinvested would have grown to approximately $50,519 today.
VRTX Dividend vs Peers
Comparable companies in the same industry
VRTX Annual Dividend History (1991–2025)
35 years of dividend data
| Year | DPS | YoY | Pmts | EPS | Payout | Coverage | YOC |
|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | — | 0 | $15.32 | — | — | — |
| 2024 | $0.00 | — | 0 | $-2.08 | — | — | — |
| 2023 | $0.00 | — | 0 | $13.89 | — | — | — |
| 2022 | $0.00 | — | 0 | $12.82 | — | — | — |
| 2021 | $0.00 | — | 0 | $9.01 | — | — | — |
| 2020 | $0.00 | — | 0 | $10.29 | — | — | — |
| 2019 | $0.00 | — | 0 | $4.51 | — | — | — |
| 2018 | $0.00 | — | 0 | $8.09 | — | — | — |
| 2017 | $0.00 | — | 0 | $1.04 | — | — | — |
| 2016 | $0.00 | — | 0 | $-0.46 | — | — | — |
Full VRTX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See VRTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VRTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VRTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVRTX — Frequently Asked Questions
Quick answers to the most common questions about buying VRTX stock.
How much dividend does VRTX pay per share?
Vertex Pharmaceuticals Incorporated (VRTX) pays a trailing 12-month dividend of N/A per share, with a current dividend yield of N/A. Payments are made quarterly.
When is VRTX's next ex-dividend date?
VRTX's most recent ex-dividend date is N/A. You must own shares before the ex-dividend date to receive the next payment. VRTX typically pays dividends quarterly.
Is VRTX's dividend safe?
VRTX's dividend safety is rated "Unknown" based on an earnings payout ratio of N/A and FCF payout ratio of N/A. The dividend history does not yet show a prolonged growth streak.
How many years has VRTX increased its dividend?
VRTX has not maintained a consecutive growth streak recently. The 5-year dividend CAGR is N/A.
How often does VRTX pay dividends?
Vertex Pharmaceuticals Incorporated pays dividends quarterly. The trailing 12-month total is N/A per share. Dividend data on this page covers 34+ years from 1991 to 2025.
How much would $10,000 invested in VRTX grow with dividend reinvestment?
With dividends reinvested (DRIP), $10,000 invested in VRTX five years ago would be worth approximately $19,842 today. This includes both price appreciation and compounded dividend reinvestment. Use the DRIP calculator above for other time periods.
What is VRTX's yield on cost for long-term holders?
VRTX's yield on cost — the current dividend divided by the original purchase price — is N/A for a 5-year holding period. This means long-term holders earn a higher effective yield than today's N/A market yield, thanks to the lower original cost basis.